key: cord-0886008-lehzj4d8
authors: Yuin Ho, Jessica Sook; Wing-Yee Mok, Bobo; Campisi, Laura; Jordan, Tristan; Yildiz, Soner; Parameswaran, Sreeja; Wayman, Joseph A.; Gaudreault, Natasha N.; Meekins, David A.; Indran, Sabarish V.; Morozov, Igor; Trujillo, Jessie D.; Fstkchyan, Yesai S.; Rathnasinghe, Raveen; Zhu, Zeyu; Zheng, Simin; Zhao, Nan; White, Kris; Ray-Jones, Helen; Malysheva, Valeriya; Thiecke, Michiel J.; Lau, Siu-Ying; Liu, Honglian; Zhang, Anna Junxia; Chak-Yiu Lee, Andrew; Liu, Wen-Chun; Jangra, Sonia; Escalera, Alba; Aydillo, Teresa; Melo, Betsaida Salom; Guccione, Ernesto; Sebra, Robert; Shum, Elaine; Bakker, Jan; Kaufman, David A.; Moreira, Andre L.; Carossino, Mariano; Balasuriya, Udeni B.R.; Byun, Minji; Albrecht, Randy A.; Schotsaert, Michael; Garcia-Sastre, Adolfo; Chanda, Sumit K.; Miraldi, Emily R.; Jeyasekharan, Anand D.; TenOever, Benjamin R.; Spivakov, Mikhail; Weirauch, Matthew T.; Heinz, Sven; Chen, Honglin; Benner, Christopher; Richt, Juergen A.; Marazzi, Ivan
title: TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
date: 2021-03-30
journal: Cell
DOI: 10.1016/j.cell.2021.03.051
sha: 40f89ded8d6be87aaf061d1ef7e0b2dc2c19156c
doc_id: 886008
cord_uid: lehzj4d8

The ongoing pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is currently affecting millions of lives worldwide. Large retrospective studies indicate that an elevated level of inflammatory cytokines and pro-inflammatory factors are associated with both increased disease severity and mortality. Here, using multidimensional epigenetic, transcriptional, in vitro and in vivo analyses, we report that Topoisomerase 1 (TOP1) inhibition suppresses lethal inflammation induced by SARS-CoV-2. Therapeutic treatment with two doses of Topotecan (TPT), a FDA-approved TOP1 inhibitor, suppresses infection-induced inflammation in hamsters. TPT treatment as late as four days post-infection reduces morbidity and rescues mortality in a transgenic mouse model. These results support the potential of TOP1 inhibition as an effective host-directed therapy against severe SARS-CoV-2 infection. TPT and its derivatives are inexpensive clinical-grade inhibitors available in most countries. Clinical trials are needed to evaluate the efficacy of repurposing TOP1 inhibitors for severe COVID-19 in humans.

Early Phase (Infection Epithelial Cells) Infection causes a rapid and orchestrated gene induction governed by expression of 109 antiviral and inflammatory mediators. This is often referred to as "infection-induced gene 110

program". In many instances, the magnitude of induction of the inflammatory 111 components in a gene program can be overwhelming and become more harmful than 112

protective. Such overt induction of inflammatory genes can be driven by unique features 113 of the infectious agent; For example, viral antagonism in infected cells may delay initial 114 responses, causing inappropriate and prolonged production of pro-inflammatory genes 115

and immunopathology later in infection (Channappanavar et al., 2016; Channappanavar 116 and Perlman, 2017) . Alternatively, excessive inflammation may be immune-mediated 117

and driven by excessive local or systemic recruitment and activation of immune cells.

The ultimate result is an overt expression of inflammatory mediators that is fatal to the 119 host. scenario is when the gene programs are triggered by non-infected immune cells that 138 respond to pathogen associated molecular patterns (PAMPs) or damage associated 139 molecular patterns (DAMPs) in an overwhelmingly inflammatory fashion. This latter 140 scenario occurs in many instances of infection that leads to sepsis. 141 142 We have previously shown that the host enzyme topoisomerase 1 (TOP1) is required to compromising pathogen clearance. At that time, 2016, we also predicted that this 150 strategy could be useful for future pandemics. We present here a series of experiments 151 in which we tested the hypothesis that modifying the host response to SARS-CoV-2 152 infection with epigenetic therapy can ameliorate severe COVID-19. 153 154 RESULTS 155

Cell signaling cascades converge on chromatin to dictate changes in gene expression 156 upon cell intrinsic and extrinsic signals. Gene expression programs are controlled by 157

transcriptional activity, which are, in turn, influenced by changes in chromatin structural 158

(physical movement of genes into chromatin compartments, or enhancer-promoter 159 interaction) and functional (epigenetic modifications that demarcate regions of gene 160 activity) organization.

Comparison between how a signal is received and decoded at the chromatin level, and 163

the final output of gene expression can elucidate how a pathogen alters the host gene 164 expression program during infection. More importantly, it can instruct the targeting of 165 chromatin factors in order to achieve a partial suppression (buffering) of infection-166

induced gene expression programs.

In an effort to understand how SARS-CoV-2 alters chromatin function and gene activity 169 upon infection, we performed a combined structural and epigenetic analysis during 170

infection.

To first characterize structural chromatin changes, we performed Hi-C on uninfected 173

and SARS-CoV-2 infected A549 cells expressing the human SARS-CoV-2 entry 174 receptor ACE2 (A549-ACE2) at both early (8 hour) and late (24 hour) time points post-175

infection. Reproducible results were achieved across replicates for all time points. 176 (Table S1) there were significant changes in K27ac levels at promoters and other regulatory 203

regions during the course of infection (clusters ii to vii; Figure 1C ; Table S2A-S2C) . 204 Regions that significantly gain (clusters v and vi; Figure 1C ) and lose K27ac (clusters ii 205 and iii; Figure 1C ) over the course of infection were detected. 206 207

We then combined structural and functional information by overlaying the changes in 208

K27ac and DNA topology. Our analysis indicates that regions that gain or lose K27ac 209 are enriched in chromatin domains that move from B-A (inactive to active) or A-B (active 210

to inactive) compartments, respectively ( Figure 1E ). This partitioning occurs 211 dynamically throughout infection ( Figure 1E -compare 8h vs 24h) and is associated with 212 gene expression activity ( Figure 1F ). These results suggest that the dynamic 213 restructuring of genome compartmentalization by SARS-CoV-2 infection is highly 214 associated with transcriptional activity.

To characterize whether a unique set of transcription factors might drive these changes 217

we performed motif enrichment analysis of regions displaying differential H3K27ac 218 activity. Our results indicate that repressed regions lack unique enrichment of immune-219 specific transcription factors at promoters, enhancers, and other putative regulatory 220 regions ( Figure S1D , Table S2D ). Regions that gain K27ac signal display a strong 221 enrichment for motifs recognized by NF-kB (red bars), AP1 (orange bars), and to a 222 lesser extent IRF and STAT transcription factors (green and blue bars respectively, 223

cluster v and vi; Figure S1D , Table S2D ). This data suggests that the epigenetic 224 landscape established as a result of the infection (and viral antagonism) is skewed 225 toward the usage of regulatory regions controlling inflammatory responses 226 227

To then provide direct evidence that identified regulatory regions do indeed contact a 228

given gene promoters to sustain gene transactivation, we performed Promoter Capture 229

Hi-C. This technique measures enhancer-promoter interactions at a single-gene 230 resolution. Promoter Capture Hi-C was conducted in SARS-CoV-2 infected A549-ACE2 231 cells at 8h and 24hpi, as well as in uninfected cells (0hpi). Following alignment and 232 quality control, we detected a total of 63,804 interactions between 11,244 promoters 233 and 40,387 promoter-interacting regions (PIRs) across the three time points using 234

CHiCAGO (Cairns et al., 2016) . Based on unsupervised clustering and post-hoc 235 filtering, we classified the promoter interactions into three broad categories based on 236 their dynamics upon infection: 10,983 "lost", 11,022 "retained" and 11,334 "gained" (see 237 STAR Methods for details).

To obtain a gene-level view, we computed the change in the number of active 240 enhancers connected to each gene between 0 and 24hpi, accounting for promoter 241 interaction rewiring and changes in enhancer activity at the PIRs of either pre-existing or 242 novel contacts. We found a significant association between this property and gene 243 J o u r n a l P r e -p r o o f expression dynamics ( Figure 1G , Fisher's test p=0.008). In particular, an increase in 244 the number of promoter-connected active enhancers associated with upregulation of 245 their respective target genes ( Figure 1G , LOR=0.74, 95% CI: 0.13-1.30). Examples of 246 the detected promoter interaction profiles at each time point for TIPARP and NFKIBIZ 247 genes that are strongly induced upon infection (log2FC>1) are shown in Figure 1H and 248 S1E respectively. 249 250

Overall (Figure 2A ) as compared to no 269 siRNA or siSCR treated cells, resulting in selective suppression of many infection-270

induced genes (Fold Change > 1.5, padj<0.05; Figure 2B and 2C, Table S3A-S3B) .

Gene ontology pathway analyses of genes that are downregulated upon TOP1 272 knockdown suggest that many of these genes are involved in inflammatory responses 273 ( Figure 2C , Table S3C ). We further validated our results by qPCR for representative 274 genes IL-6, CXCL2, CXCL3, CXCL8, EGR1 and TNFAIP3 ( Figure 2D ), verifying that 275 depletion of TOP1 protein levels ( Figure 2E ) reduces the expression of these 276 inflammatory genes.

To understand the specificity of TOP1, we profiled infection induced and TOP1 279 dependent genes ("Dep."; Table S3D ) identified in Figure 2B with respect to their 280 structural and epigenetic status at basal state and after infection. As controls, we used 281 all expressed genes ("Exp"; Table S3D ) or genes that are also induced by infection but 282 unaffected by TOP1 depletion (TOP1 independent, "Indep."; Table S3D ). Our analysis 283

indicates that genes that depend on TOP1 for their upregulation are induced to higher 284 levels then TOP1 independent genes upon infection ( Figure 2F ). TOP1 dependent 285

genes also displayed greater shifts towards active chromatin compartment (positive 286 delta PC1 levels, Figure 2G ) and increases in K27ac signals (positive delta H3K27ac 287 levels; Figure 2H ) and an increase in number of enhancers (Wilcoxon p=0.015) 288

compared to TOP1 independent genes. These differences are typical features of genes 289 To determine whether inhibition of TOP1 activity phenocopies depletion of TOP1 and 293 dampens inflammatory gene expression, we treated SARS-CoV-2 infected A549-ACE2 294 cells with topotecan (TPT), a FDA approved TOP1 inhibitor. TPT treatment, unlike 295 DMSO treatment, dampens the expression of IL-6, CXCL2, CXCL3, CXCL8, EGR1 and 296 TNFAIP3 (Figure S2A) , similar to what we observed in siTOP1 treated cells ( Figure 2B  297 and 2D). Reduced inflammatory gene expression was not a result of a direct antiviral 298 effect of TPT. Unlike remdesivir, a drug with known antiviral activity towards SARS-299

CoV-2, TPT does not inhibit viral replication ( Figure S2B-S2C We treated SARS-CoV-2 infected hamsters with either vehicle control (DMSO) or 310

10mg/kg TPT at days 1 and 2 post-infection. Lungs from these animals were then 311 collected for histology and transcriptome analysis at days 4 and 6 post-infection ( Figure  312 3A).

Clustering of RNA-seq reads using principal component analysis (PCA) indicates that 315 the gene expression profiles under the three conditions (uninfected, infected-DMSO 316 treated, and infected-TPT treated) partition based on infection, treatment status, and the 317 temporality of the infection (day 4 and 6), with each replicate clustering in close 318 proximity to its counterpart ( Figure 3B ). 319 320

Differential expression (DE) analysis showed that TPT suppresses inflammatory gene 321 expression in the lungs of infected hamsters (Figure 3C and 3D; Tables S4A and  322 S4B). Clustering of the DE data indicates that the gene expression profiles of TPT-323 treated infected lungs are more similar to that of the non-infected lungs, rather than 324 infected ones ( Figure 3C ). The GO categories associated with the TPT-suppressed 325 genes indicates specific inhibition of virus-induced and inflammatory genes at both day 326 4 and day 6 post-infection ( Figure 3D ; Tables S4C and S4D) .

Histopathological analysis of infected, DMSO vehicle-treated hamster lungs at days 4 329 and 6 post-infection displayed diffused alveoli destruction, bronchiolar epithelium cell 330 death and hemorrhaging, coupled with massive immune cell infiltration and exudation, 331

typically associated with increased expression of inflammatory mediators and 332 recruitment of immune cells during infection (Figure 3E and 3F) . On the contrary, TPT 333 treatment diminished pathological features of lung damage in infected animals. Lungs 334 from these animals did not have conspicuous alveolar space infiltration, exudation or 335 hemorrhaging at both days 4 and 6 post infection (Figure 3G and 3H) .

To determine the clinical significance of our observations, we then asked if the genes 338 that were downregulated by TPT treatment in SARS-CoV-2 infected hamsters also 339 corresponded to immunopathological gene signatures that have been observed in 340 COVID-19 patients. Cross-comparison of our results with the gene expression profiles 341

in human lungs isolated from autopsies of COVID-19 patients and uninfected control 342 lungs (Nienhold et al., 2020) indicated that TPT suppressed genes are hyperactivated in 343

patients who succumbed to infection (Figure 4A and 4B) . In fact, TPT-inhibited genes 344

are genes that are up-regulated in COVID-19 lung autopsy tissue relative to healthy 345 control (p<1E-3) ( Figure 4A, left panel) , while genes up-regulated by TPT are down-346 regulated in COVID-19 lung relative to control (p<1E-7) ( Figure 4A, right panel) . These 347 results suggest that treatment with TPT might reverse COVID-19-induced lung gene 348 expression responses. The gene expression profiles of TPT inhibited genes in individual 349 patients (heatmap, Figure 4B ) and the corresponding gene set enrichment scores are 350

shown in Figure 4B . isolated from severe COVID19 cases, and not in healthy controls ( Figure S3A and B).

Notably an ISG signature appears to mainly reside in phagocytes; however, the nature 367 of the cells that produce the interferons and the nature of the interferons themselves 368 that drive ISGs remain largely unknown.

Immune cells are unlikely to be productively infected by SARS- or in response to supernatant from productively infected cell ( Figure S3C ). We were 378 unable to detect productive SARS-CoV-2 infection of these cells, in line with previous 379

reports ( Banerjee et al., 2020a) . Overall, our analyses support the idea that TPT is 380 active in both epithelial and immune cells and suppresses inflammatory gene programs 381

induced by the infection.

We next sought to validate whether lower dosages of TPT, which are associated with performed a parallel experiment to the one described in Figure 3A using 5-fold lower 387

dose of TPT (2mg/kg) and the same regimen of TPT treatment at Day 1 and 2 post-388 infection ( Figure S4A ). Lungs from infected and treated hamsters were assayed at Day 389 4 post infection.

Animals treated with TPT had reduced lung to body weight ratios post infection ( Figure  392 S4B), which suggest reduced pulmonary edemas in these animals. In line with this, 393

histopathological analyses showed reduced broncho-pneumonia ( Figure S4C-S4E ) and 394

immune cell infiltration (Table S5 ) in the lungs of TPT treated animals when compared 395

to DMSO treated ones. qPCR analysis of representative genes also suggested reduced 396 expression of inflammatory genes in TPT treated animals ( Figure S4F ).

Gene suppression and reduced lung damage occurred despite of a moderate 3-fold 399

increase virus growth at day 4, where both TPT and DMSO treated lung display similar 400 viral titer. By day 8, virus growth in both TPT and DMSO treatment ceased to an 401 undetectable level (Figure S4G) Figure 5A and S5A ).

The rationale behind this approach is that inhibition of inflammation could be detrimental of weight loss (p=0.0028, Two way ANOVA (mixed effects)).

Strikingly, we found that late TPT treatment provided significant survival benefit 439 (p=0.0085, Log-rank Mantel-Cox) to infected mice when compared to DMSO vehicle 440 treated controls ( Figure 5B ). In addition, TPT significantly improved morbidity outcomes 441 in infected mice; Despite an overall delay in weight loss kinetics in TPT mice ( Figure  442 5C), fewer mice lost >15% of their body weights compared to DMSO treated mice 443

( Figure 5D ; p=0.0409, Fishers' Exact Test). Importantly, TPT administration neither 444

significantly changed viral titers immediately after treatment (day 7 post infection, 445 Figure 5E ), nor did it delay viral clearance kinetics as no detectable virus, as measured 446 by plaque assays, was found in the lungs of both TPT and DMSO treated mice by day 447

14 post infection ( Figure 5E ). As expected, TPT treatment was also associated with 448

suppression of inflammatory gene expression in the lung, as indicated by qPCR of 449

representative genes ( Figure 5F ) and supporting our initial hypotheses.

Finally, we assessed longer term effects of TPT treatment in mice. TPT treated mice 452

survived past 9 weeks post infection with similar post-recovery weight gain levels 453

( Figure 5G ) to that of DMSO treated mice. Neutralizing antibody activity in the blood of 454 DMSO and TPT treated mice were found to be at similar levels at 5 weeks post infection 455 ( Figure 5H) promoters and enhancers, enhancer-promoter interactions and transcriptional induction.

Gene suppression has functional consequences as it affects many conventional 499

infection-induced genes activated by STAT1/2 and IRF3 transcription factors. 500

Suppression is likely a result of viral antagonism. Gene activation is the result of signal-501

induced transactivation, and indicates that many cellular genes escape viral 502 suppression during infection. One prominent example is a subset of inflammatory genes 503 whose expression is driven by infection-activated transcription factor NF-kB. The 504

proteins encoded by these genes are potent pro-inflammatory molecules and present 505 systemically with high levels in severe COVID19 patients (Del Valle et al., 2020; Moore 506

and June, 2020). The selective and concerted induction of inflammatory genes provides 507 the rationale for using epigenetic inhibitors to suppress their induction and establish a 508 global anti-inflammatory state (Marazzi et al., 2018).

Inflammatory gene suppression therapy 511

We show that the host enzyme TOP1 promotes transcriptional activation of pro-512 inflammatory genes during SARS-CoV-2 infection. We then demonstrate that TOP1 513

inhibition limits the expression of inflammatory genes in the lungs of infected animals. 514

Most importantly, TOP1 inhibition decreases morbidity and morbidity in infected mice. 515

The therapeutic effect can be achieved by drug administration 4-5 days following 516

infection. 517 J o u r n a l P r e -p r o o f 518 The suppression of inflammation in vivo is most likely not solely the result of dampened 519 epithelial response, but also neutrophil/monocytic cell activation and response. Based 520 on our experiments and gene signature analyses of specific-cell types, we posit that 521

TPT suppresses inducible transcriptional programs in both infected and bystander cells. 522

Dampening highly inducible genes and sparing housekeeper genes is a typical feature 523

of epigenetic inhibitors that act on signal-induced genes, which aside from the 524 requirement of cofactors for their activation have unifying genomic features like high Lethal inflammation in severe COVID19 has been associated with the dysregulation of 529 multiple inflammatory genes, including IL6, IL1, IL10. However, many of the current 530 strategies proposed to treat severe COVID19, such as anti-IL6 (e.g. tocilizumab, 531 sarilumab) or anti-IL1 (e.g. anakinra) inhibitors, are directed against single inflammatory 532 mediators and specific gene expression programs. The effects of such drugs may be 533 undermined by alternative gene activation pathways driven by other 534

cytokines/transcription factors.

In contrast, TPT functions to broadly dampen inflammatory gene expression programs, 537 regardless of the cell or activation pathways. Inhibition of systemic inflammation using 538 the glucocorticoid dexamethasone, has been shown to provide survival benefit to 539

severe COVID19 patients, suggesting that this is indeed a viable strategy. That being 540 said, it is important to note that TPT and glucocorticoids have different molecular targets 541

and exert anti-inflammatory effects via different molecular mechanisms of action.

Finally, TPT and other TOP1 inhibitors like irinotecan are widely available and FDA-544

approved. Irinotecan is in the WHO list of Essential Medicines. They are inexpensive 545

and generic formulation exists throughout the world, making them easily accessible for 546 immediate use. Overall, our results suggest that repurposing of TOP1 inhibitor could be 547 a valuable strategy to treat severe COVID-19. 548 549

Limitations of this study 550

Our study indicates a promising effect of TPT in COVID19 in preclinical animal models.

As any animal model, they are only partially representative of the biology of humans. In 552 our animal models, we can suppress inflammation and reduce disease pathology in the 553 lung using 2 doses of TOP1 inhibition therapy with TPT at 2mg/kg intraperitoneally. This 554 equates to a 5-fold reduction from typical chemotherapeutic anti-cancer doses in rodent irinotecan in COVID-19 patients will need to be performed prior to testing efficacy.

Another important consideration is that the window of opportunity for TOP1 inhibitor 567 treatment in humans needs to be carefully evaluated. Many reports indicate that the 568 timing of the intervention against Coronaviruses is key, as protective anti-viral and 569

damaging excessive inflammatory responses need to be balanced (Channappanavar et aligns with those studies, as early treatment of TPT did not display protective effect in 572 mice.

In essence, stratification of patients based on inflammatory marker is key, as 575

suppressing gene programs too early during infection might compromise antiviral 576

response together with limiting inflammatory responses, with the unwanted effect of 577

increasing viral replication and dissemination. Accordingly, studies with glucocorticoids 578

can lead to increase in viral persistence in convalescent severe patients. Similarly, 579 corticosteroid treatment has been suggested to have negative effects post-recovery in 580

patients with non-severe COVID19.

In line with this, inhibition of inflammation by TPT or other molecules that lower systemic 583 inflammation could theoretically lead to a resurgence in viral replication and 584

administration of an anti-viral agent with activity against SARS-CoV-2 after anti-585 inflammatory therapy should be used.

The safety and efficacy of our strategy will now be evaluated in two clinical trials of TPT We with hamsters in Figure S4 and all infections in K18-hACE2 mice (Figures 5 and S5) , 948

isolate USA-WA1/2020 (NR-52281) was used. SARS-CoV-2 was grown in Vero E6 cells 949

in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM 950 non-essential amino acids, 1 mM sodium pyruvate and 10 mM HEPES. Plaque assays 951

were

Minimum Hamsters were anesthetized with ketamine (150mg/kg) and xylazine (10 mg/mg) and 1112 then intranasally inoculation with 50 ul of diluted viruses containing 10 3 PFU of viruses. 1113

For drug treatments, 10mg/kg TPT resuspended in vehicle [5% DMSO + 5% corn oil in 1114 PBS] or vehicle alone was administered intraperitoneally to animals on the indicated 1115 days post infection.

For experiments shown in Figure S4 , Upon euthanasia, the superior lobe of infected hACE2-KI mice or Golden Syrian 1152 hamsters were collected for RNA extraction. Lungs were lysed and homogenized in 1153

Trizol. RNA extraction was performed using the Purelink RNA Mini Kit with a DNAseI 1154 treatment step, according to the manufacturer's recommendations. cDNA was 1155 synthesized from RNA using the High-Capacity cDNA Reverse Transcription Kit 1156 (ThermoFisher).

Histological analysis 1159

For histological slides shown in Figure 3E to 3H, Lung left superior lobes of infected 1160

Golden Syrian hamster were fixed in 4 % paraformaldehyde and then processed for 1161 paraffin embedding. The 4µm tissue sections were stained with haematoxylin and eosin 1162

for histopathological examination. Images were with Olympus BX53 semi-motorized 1163 fluorescence microscope using cellSens imaging software.

For histological slides shown in Figure S4D and S4E, the left lung lobe of infected 1166

Golden Syrian hamsters was fixed in 10% formalin for 48 hours. Embedding in paraffin 1167 blocks and staining with H&E were conducted by the Biorepository and Pathology 1168

Dean's CoRE at the the Icahn School of Medicine at Mount Sinai. Microscopic sections 1169

were analyzed in a blinded fashion by the same pathologist (A.M.). A number was 1170 randomly assigned by the investigator to discriminate each section, which was then 1171

submitted for analysis. No information about treatments and mouse genotypes was 1172 communicated to the pathologist. Lungs were scored by the area involved in broncho-1173

pneumonia.

Promoter Capture Hi-C (PCHi-C) 1176 We combined PCHi-C (Schoenfelder et al., 2015) with Hi-C library generation as 1177 described previously (Nagano et al., 2017), with some modifications. Cells were fixed in 1178 2% PFA for 10 minutes, lysed in lysis buffer (30 minutes on ice), and digested with 1179

DpnII (NEB) overnight at 37C rotating (950rpm). Restriction overhangs were filled-in 1180

with Klenow (NEB) using biotin-14-dATP (Jena Bioscience), and ligation was performed 1181

in ligation buffer for 4 hours at 16C (T4 DNA ligase; Life Technologies). After overnight 1182 decrosslinking at 65C, the ligated DNA was tagmented to produce fragments of 300-700 1183 bp range. Ligation products were isolated using MyOne C1 streptavidin beads (Life 1184 Technologies), followed by washing with Wash&Binding buffer and nuclease-free water. 1185

Isolated Hi-C ligation products on the beads were then used directly for PCR 1186 amplification, and the final Hi-C library was purified with AMPure XP beads (Beckman 1187

Coulter). Promoter Capture Hi-C was performed using a custom-design Agilent 1188

SureSelect system following the manufacturer's protocol.

Quantification of viral titers by plaque assays 1191

For quantification of viral titers in the lungs tissues of infected animals, the middle, 1192

inferior and post-caval lobes of infected mice/hamsters were collected and 1193

homogenized in 1ml of ice-cold PBS. Lysates were then centrifuged at 10000rpm for 1194 5min to remove cellular debris, and the cleared lysates transferred to new tubes. 1195

Lysates were then diluted in 10 fold dilutions 6 times. Quantification of infectious SARS-1196

CoV-2 titers was then performed by plaque assays. Briefly, Vero-E6 cells were plated 1197 as confluent monolayers in 12 well dishes. Media was removed, and wells washed in 1198

1ml of PBS. 200ul of diluted lysates was then added per well and allowed to incubate 1199

for 1 hour at 37 o C. After viral adsorption, lysates were removed from the well and cells 1200

were overlaid with Minimum Essential Media supplemented with 2% FBS, 4 mM L-1201 glutamine, 0.2% BSA, 10 mM HEPES and 0.12% NaHCO3 and 0.7% agar. 72h post 1202

infection, agar plugs were fixed in 10% formalin for 24h before being removed. Plaques 1203

were visualized by immune staining with anti-mouse SARS-CoV-2 Nucleoprotein 1204 antibodies (mAb 1C7) for 1 hour at RTP followed by anti-mouse HRP-conjugated 1205 secondary antibody (abcam) for 1 hour at RTP after 3 washes in PBS + 0.1% Tween 1206 20. Plaques were then developed using the TrueBlue substrate (KPL-Seracare) and 1207 viral titers calculated and expressed as PFU/ml 1208 1209

Quantification of neutralizing antibodies in serum (Microneutralization Assays) 1210

Microneutralization assays were performed as previously described(Amanat et al., 1211 2020). Briefly, Vero E6 cells were seeded at a density of 20,000 cells per well in a 96-1212

well cell culture plate in complete Dulbecco's Modified Eagle Medium (cDMEM). The 1213

following day, heat-inactivated serum samples (dilution of 1:10) were serially diluted 1214 threefold in 1× MEM (10% 10× minimal essential medium (Gibco), 2 mM L-glutamine, 1215 0.1% sodium bicarbonate (wt/vol; Gibco), 10 mM 4-(2-hydroxyethyl)-1-1216 piperazineethanesulfonic acid (HEPES; Gibco), 100 U ml-1 penicillin, 100 ug/ml-1 1217 streptomycin (Gibco) and 0.2% bovine serum albumin (MP Biomedicals)). Then, 80 μl 1218 of each serum dilution and 80 μl of the SARS-CoV-2 virus, diluted to a concentration of 1219 100 TCID50 (50% tissue culture infectious dose) were added to a 96-well cell culture 1220

plate and allowed to incubate for 1 h at room temperature. Media was then removed 1221 from the Vero E6 cells, and 120ul of the virus-serum mixture added to each well. The 1222

plate was then incubated at 37 °C for 1 h. Virus-serum mixture was then removed from 1223 the cells, and 100ul of each corresponding serum dilution and 100ul of 1X MEM/1%FBS 1224 added back to each well. Cells were incubated for 48h at 37 °C before being fixed with 1225

10% paraformaldehyde for 24h at 4 o C. After fixation, formaldehyde was removed, and 1226 cells were washed with 200ul PBS, before being permeabilized with 150ul PBS/0.1% 1227

TritonX-100 for 15min. Plates were then washed three times with PBS + 0.1% Tween 1228 20 (PBST) and blocked in 3% Milk/PBST for 1h at RTP. 100ul of 1:1000 diluted mAb 1229

1C7 iwas then added to each well. Plates were incubated for a further 1h at RTP. After 1230 incubation, plates were wash 3 times with PBST, before anti-mouse IgG-HRP (1:3000 in 1231 3% milk) was added to the well. Plates were incubated for a further 1 hour at RTP, 1232 before being washed 3 times with PBST. Finally, SIGMAFAST OPD (Sigma-Aldrich) 1233

was added to wells. The reaction was stopped after 10 min through the addition of 50ul 1234 3M HCl. OD490 was then measured on a Synergy 4 plate reader (BioTek). 1235

Concentrations of antibodies in serum were blank normalized and curve-fitted to 1236 calculate IC50 using Graphpad prism 8.0. SARS-CoV-2 (isolate USA-WA1/2020 (NR-52281)) in 50ul, bringing the final drug 1268 concentration to those indicated. Plates were then incubated for 48h at 37 °C, 5% CO2. 1269

Supernatants were then removed and cells were fixed in 4% paraformaldehyde for 24h. 1270

To determine % of infected cells, cells were stained for NP protein (1° antibody: anti-1271 sera produced in the García -Sastre laboratory; 1:10,000; 2° antibody: anti-rabbit Alexa 1272 flour 488nM) and a DAPI counterstain. Infected cells were visualized and quantified 1273

using the Celigo (Nexcelcom) imaging cytometer. Accumulation of viral NP protein in 1274 the nucleus was used as a proxy for infectivity. The percentage of infected cells per well 1275 was quantified as ((infected cells/total cells) − background) × 100 and the DMSO control 1276

was then set to 100% infection for analysis. The IC50 was then determined using 1277

Graphpad Prism 8.0 software by performing a non linear regression (inhibitor vs 1278 response) curve fit. To measure cytotoxicity of drugs, MTT assays (Roche) were 1279 performed according to the manufacturer's instructions. These assays were performed 1280 in uninfected Vero-E6 cells using the same concentrations of drugs, and performed 1281

concurrently with viral replication assays. All assays were performed in biologically 1282 independent triplicates. 1283 1284 QUANTIFICATION AND STATISTICAL ANALYSES 1285

Mouse Infection Studies 1286

Mice were randomly assigned into treatment groups. Statistical significance between 1287 survival curves was calculated using a Log-rank (Mantel-Cox) test using Graphpad 1288

Prism 8.0 software. Differences in weight loss curves were determined using a Two-1289

Way Figure 1 ) 1524 Table of processed Hi-C data used to derive panels shown in Figure 1 . conditions. Detailed Column descriptions are as follows 1531 1532 Table S2 : H3K27ac ChIP-seq QC summary and differential peak analyses (Related 1533

to Figure 1 and S1) 1534 Table S2A : QC analysis and statistics of H3K27ac ChIP-seq data 1535 Table S2B : Full results of H3K27ac differential peak analysis (Contrast 8h vs 0h) 1536 Table S2C : Full results of H3K27ac differential peak analysis (Contrast 24h vs 0h) 1537 Table S2D : Table S3C : Gene ontology (pathway) analyses pathway analysis for downregulated 1560 genes listed in Figure 2B and Tables S4.  1561  Table S3D : Gene lists for all expressed, TOP1 dependent and TOP1 independent 1562

genes. Shown are the log2FC, AveExpr, t-stat, p-values, adjusted p-values and B-stats 1563

for the siSCR infected vs siSCR uninfected contrast, used to define infection induced 1564

genes. Genes that are induced by infection are indicated by "1" in Column I. Genes that 1565 J o u r n a l P r e -p r o o f are TOP1 dependent and induced by infection are indicated by "1" in Column J. Genes 1566 that are Infection induced and TOP1 independent are indicated by "1" in Column K. 1567 1568 Table S4 : Differential expression analysis (RNA-seq) for TPT and DMSO treated 1569 hamsters at Days 4 and 6 post infection (Related to Figure 3 ) 1570 Figure 3 and S4D-S4E) 1593

Scoring of H&E stained lung sections taken from hamsters infected with SARS-CoV-2 1594

and treated with vehicle (DMSO) or 2mg/kg TPT at days 1 and 2 post infection. Lung 1595 sections were isolated on day 4 post infection.

Please upload a single Word document that includes your Highlights. Highlights are 3-4 bullet points of no more than 85 characters in length, including spaces, and they summarize the core results of the paper in order to allow readers to quickly gain an understanding of the main take-home messages. HERC6  IFIT3  DDX58  OAS2  IFIT2  ISG15  MX1  TAP1  CXCL10  CXCL11  IDO1  CCR1  PSMB9  ARG1  FCGR3B  SELL  ITGAX  CD53  CD37  CCL18  CD68  C1QB  MKI67  CD38  GZMA  CCR5  FCER1G  CTSS  AIF1  TYROBP  CCL4  NKG7  IL2RG  PTPN7  CORO1A CCR2 HLA DMA IL10RA CLEC5A  KCNK13  P2RY1  CD300C  RAB7B  NFKBIE  RAP2B  HLA DRB5  MS4A4A  FABP5  NEK6  CTSH  LILRB5  CHI3L1  CTSK  AL049634.2  HLX  GPR84  NFIL3  CYP1B1  CCL7  SPP1  ACOD1  SLC37A2  PLA2G7  GNS  MMP19  TM4SF19  SDC3  CD209  HLA DQB2  CLEC6A  P2RY12  MS4A4E  BZW2  GPR183  TIFAB  SNX22  UBD  MOB1A  CNDP2  CXCL10  CXCL11  IDO1  SERPINB9  ATF3  SPHK1  TPD52L2  SOD2  SAT1  CCL2  CCL8  PFKFB3  FCGR3B  FFAR2  TNFRSF14  IRF1  TAGAP  HIF1A  ISG15  ZC3HAV1 

A serological assay to 1600 detect SARS-CoV-2 seroconversion in humans

The ENCODE Blacklist: Identification of 1602 Problematic Regions of the

CPT-11 (irinotecan) addition to bimonthly, 1605 high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated 1606 metastatic colorectal cancer. GERCOR

Isolation, Sequence, Infectivity, and Replication 1609

Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2

SARS-CoV-2 Disrupts Splicing

Translation, and Protein Trafficking to Suppress Host Defenses

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Imbalanced Host Response to SARS-CoV-2 1618

Drives Development of COVID-19

Host-Viral Infection Maps Reveal Signatures of Severe 1621 COVID-19 Patients

Effect of anakinra versus usual care in adults in 1624 hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised 1625 controlled trial. The Lancet Respiratory Medicine

CHiCAGO: robust detection of DNA 1628 looping interactions in Capture Hi-C data

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses 1631

Cause Lethal Pneumonia in SARS-CoV-Infected Mice

IFN-I response 1634 timing relative to virus replication determines MERS coronavirus infection outcomes

Pathogenic human coronavirus infections: 1637 causes and consequences of cytokine storm and immunopathology

Clinical and immunological features of severe and moderate coronavirus 1641 disease 2019

Enhancer Histone Acetylation 1644

Cytokine responses in severe acute respiratory syndrome 1648 coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Identification of Required Host Factors for SARS-1652

CoV-2 Infection in Human Cells

An inflammatory cytokine signature 1655 predicts COVID-19 severity and survival

STAR: ultrafast universal RNA-seq aligner

Enhancer Control of Transcriptional Bursting

COVACTA trial raises questions about tocilizumab's benefit in COVID-19

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

A SARS-CoV-2 protein interaction map 1669 reveals targets for drug repurposing

Interferon responses in viral pneumonias

Association Between 1674

Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With 1675 COVID-19: A Meta-analysis

Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: 1678 pharmacokinetic and pharmacodynamic evaluation

Simple combinations of lineage-determining transcription 1681 factors prime cis-regulatory elements required for macrophage and B cell identities

Transcription Elongation Can Affect 1685

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 1688 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, 1691 administered at low dose levels in protracted schedules to mice bearing xenografts of human 1692 tumors

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 1695 Lancet

Syrian hamsters as a small animal model for 1698

SARS-CoV-2 infection and countermeasure development

Topotecan -A 1701 novel topoisomerase I inhibitor: pharmacology and clinical experience

Fast gene set enrichment analysis. 1703 bioRxiv

Similarity regression predicts evolution of 1706 transcription factor sequence specificity

Fast gapped-read alignment with Bowtie 2

voom: Precision weights unlock linear 1710 model analysis tools for RNA-seq read counts

Coronaviruses: Innate Immunity

cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung 1828 cancer

Correlation 1830 analysis between disease severity and clinical and biochemical characteristics of 143 cases of 1831 COVID-19 in Wuhan, China: a descriptive study

HiCUP: pipeline for mapping and processing Hi-C data

SARS-CoV-2 infection of human ACE2-transgenic 1836 mice causes severe lung inflammation and impaired function

Plasma inflammatory cytokines and chemokines in severe 1839 acute respiratory syndrome

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict 1842 the progression of COVID-19

clusterProfiler: an R package for comparing 1844 biological themes among gene clusters

Enhancer-core-promoter specificity separates developmental and housekeeping gene 1847 regulation

Model-based analysis of ChIP-Seq (MACS)

Clinical course and risk factors for mortality of adult inpatients with

China: a retrospective cohort study

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe 1856 COVID-19 patients

From SARS and MERS to 1858 COVID-19: a brief summary and comparison of severe acute respiratory infections caused by 1859 three highly pathogenic human coronaviruses

After adaptor removal with cutadapt (Martin, 2011) and base-quality trimming to remove 1345 3′read sequences if more than 20 bases with Q <20 were present, paired-end reads 1346were mapped to the SARS-CoV-2 and human (hg38) or hamster (Mesocricetus auratus; 1347MesAur1.0) reference genomes with STAR . Gene-count summaries were generated 1348 with featureCounts (Liao et al., 2014). A numeric matrix of raw read counts was 1349 generated, with genes in rows and samples in columns, and used for differential gene The ChIP-seq experimental design consisted of triplicates experiments for each 1417 condition (0hr, 8hr, 24hr infections). PCA analysis indicating strong agreement between 1418 experimental replicates and clear separation between conditions ( Figure S1A ) 1419Sequencing reads from replicates were thus combined, and alignment and peak calling 1420 was again performed as described above. For differential peak analysis, the union set of 1421 all peaks from these three conditions was generated using bedtools (Quinlan and Hall, 1422 2010). For each of the resulting genomic regions, read counts were obtained for all 9 1423replicates. These read counts used as input to DESeq2 (Love et al., 2014). A fold 1424 change cutoff of greater than or equal to 1.5 and an FDR-corrected p-value cutoff of 1425 less than or equal to 0.05 were used to identify differential peaks for each pairwise 1426 comparison between conditions. 1427 1428We used the HOMER suite of tools (Heinz et al., 2010) , modified to use a log base two 1429scoring system and to include the large set of human motifs contained in the CisBP 1430 database (build 2.0)(Lambert et al., 2019) to identify enriched motifs within the 1431 sequences of differential and shared ChIP-seq peaks. To minimize redundancy, motifs 1432were grouped into classes using the following procedure. Each human transcription 1433 factor was assigned the single best p-value obtained for any of its corresponding motifs. 1434Transcription factors with identical best motifs were merged then into a single class. any two regions across the entire chromosome were then calculated to generate a 1447 correlation matrix (also visualized in Figure 1A ). This matrix was then analyzed using from the PCA analysis due to its small size and high repeat content. Balanced, 1457normalized Hi-C contact maps were generated at 25 kb resolution for visualization 1458 (Figure 1A) . Assignment of PC1 values to Gencode gene promoters and other features 1459was performed using HOMER's annotatePeaks.pl function using the results from the 1460 PCA analysis.

Promoter Capture Hi-C analysis 1463Sequencing data from three biological replicates of PCHi-C at each of the three 1464 timepoints were aligned and quality-controlled with HiCUP (Wingett et al., 2015) . DpnII 1465 fragment-level reads were pooled over consecutive fragments over the total length of at 1466 least 5k, except for the baited promoter fragments that were left unbinned. To achieve a 1467 balanced dataset for the analysis of promoter interaction dynamics across timepoints, 1468sequencing data for each replicate were subsampled to a similar number of HiCUP-1469processed valid captured reads per timepoint. Significant interactions were then 1470 detected for each timepoint jointly across the replicates by CHiCAGO (Cairns et al., 1471 2016), with minNPerBait set to 90 and all other parameters left at defaults.

A peak matrix was generated listing the CHiCAGO scores at each timepoint for all 1474interactions that exceeded a CHiCAGO score cutoff of 5 in at least one timepoint. K-1475 means clustering was used to partition the peak matrix into 7 clusters based on arcsinh-1476transformed CHiCAGO scores, corresponding to interactions detected in a single 1477 timepoint ("0h", "8h", "24h"), two timepoints ("0+8hpi", "0+24hpi", "8+24hpi") or all 1478 timepoints ("0+8+24hpi"). To minimise the impact of false-negative calls at each 1479 timepoint on cluster assignment, we additionally called interactions in each full-sized 1480 single replicate and filtered the above clusters to remove interactions that had 1481 J o u r n a l P r e -p r o o f CHiCAGO scores above 3 in any single replicate/time point, for which the 1482 corresponding cluster was negative (e.g., interactions in the 0hpi cluster were filtered 1483 out if they had scores > 3 in any of the single-replicate 8hpi or 24hpi calls, etc.). This 1484 filtered interaction set was then curated based on their k-means cluster assignment into 1485 three categories: lost ("0hpi" and "0+8h"), retained (the "0+8+24hpi" cluster) and gained 1486 ("8+24hpi" and "24hpi"), respectively, upon infection.

To assess the relationship between H3K27ac dynamics and changes in promoter-1489 enhancer interactions at 0 vs 24 hpi, we used Fisher's test on 3x3 contingency tables 1490 between the "lost" (log2FC<-2; padj<0.05), "constant" (padj>0.1; baseMean>50) and 1491"gained" (log2FC>2; padj<0.05) H3K27ac peaks and the promoter interaction categories 1492 defined as above. Interactions without H3K27ac ChIP peaks at PIRs at either 0 or 24 1493 hpi were removed from the analysis. Results were presented as heatmaps, with each 1494 combination of expression and promoter interaction category color-coded by the log-1495 odds ratio (LORs) for the given versus the other two expression and promoter 1496 interaction categories combined, respectively. Confidence intervals (CIs) for the LORs 1497were computed based on Fisher's exact test, with LORs whose CIs cross zero greyed 1498 out on the heatmaps. 1499 1500To assess the relationship between gene expression dynamics and change in the 1501 number of connected active enhancers, we used the same promoter interaction and 1502H3K27ac dynamics categories, and additionally classified genes into "down" (log2FC<1, 1503 padj<0.05), "neutral" (|log2FC<0.5|, padj>0.2) and "up" (log2FC>1, padj<0.05) at 24 vs Genes were partitioned into three categories based on this quantity: "reduced" (C<0), 1515"constant" (C=0), "increased" (C>0). The relationship between these categories and the 1516 gene expression category ("down", "neutral", "up") was probed and visualised using 3x3 1517 contingency tables in the same manner as above. 1518 1519